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life and disability, Ethiopia
Fentie Ambaw,a Rosie Mayston,b Charlotte Hanlon,c Girmay Medhinc & Atalay Alemc
Introduction
Tuberculosis is the principal cause of death due to infectious 
disease worldwide;1 it accounts for 2.0% of the global disease 
burden, as measured in disability-adjusted life–years.2 In 
Ethiopia, tuberculosis is the fourth highest contributor to the 
disease burden.3 The World Health Organization’s (WHO’s) 
End-TB Strategy, launched in 2015, aims to achieve a treatment 
success rate of 90% by 2030 in all people with tuberculosis, 
including those with multidrug-resistant disease.1 People with 
tuberculosis often suffer from depression,4–6 which can reduce 
the likelihood of successful tuberculosis treatment,7 impair 
functioning8 and decrease quality of life.9 Systematic reviews 
have shown that depression is associated with poor medica-
tion adherence in people with human immunodeficiency virus 
(HIV) infections and acquired immune deficiency syndrome 
(AIDS).10 Moreover, in chronic noncommunicable diseases, 
depression has been observed to lead to poor treatment ad-
herence and to lower immunity through neuroendocrine and 
behavioural mechanisms.11,12 These mechanism may also have 
a detrimental effect on responses to tuberculosis treatment.
Evidence on the impact of comorbid depression in tu-
berculosis is scarce.7 Although a few studies have assessed the 
association between depression and adherence to antituber-
culosis treatment, they were limited by small sample sizes of 
less than 70 patients. One study did analyse the relationship 
between depression and death or treatment discontinuation 
in people with tuberculosis,13 but we were unable to identify 
any study that disaggregated these outcomes. Other studies 
assessed disability14 and quality of life15 cross-sectionally or 
investigated changes from baseline in these variables after 
tuberculosis treatment.8 However, they did not evaluate the 
impact of comorbid depression, which is known to be an im-
portant cause of disability and poor quality of life in people 
with chronic disorders.11 Although global plans to end tuber-
culosis stress that both a patient-centred approach and social 
support are important for maximizing the treatment success 
rate, specific recommendations for people with comorbid 
depression is lacking.1
In addition, in low-income countries like Ethiopia, there 
are large gaps in treatment for mental health problems in 
general and for depression in particular.16 However, renewed 
efforts are being made to improve the detection and treatment 
of depression in primary health-care settings through WHO’s 
Mental Health Gap Action Programme (mhGAP).17 Greater 
understanding of the effect of untreated depression on the 
management of diseases important for public health, such 
as tuberculosis, is vital and would help ensure holistic care.
The aim of this study was to examine the impact of co-
morbid depression on treatment outcomes in people with 
tuberculosis in Ethiopia and on their health-related quality 
of life and level of disability.
Methods
Between December 2014 and July 2016, we conducted a 
prospective observational study of people who were newly 
diagnosed with tuberculosis at 14 primary health-care centres 
in south central (i.e. in Silti and Gurage zones) and northern 
(i.e. Bahir Dar zone) Ethiopia. Two centres were hospitals 
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Assessment Scale. Using multivariate Poisson regression analysis, we estimated the association between probable depression at baseline 
and treatment outcomes and death.
Results Untreated depression at baseline was independently associated with tuberculosis treatment default (adjusted risk ratio, aRR: 9.09; 
95% confidence interval, CI: 6.72 to 12.30), death (aRR: 2.99; 95% CI: 1.54 to 5.78), greater disability (β: 0.83; 95% CI: 0.67 to 0.99) and poorer 
quality of life (β: −0.07; 95% CI: −0.07 to −0.06) at 6 months. Participants with probable depression had a lower mean quality-of-life score 
than those without (5.0 versus 6.0, respectively; P < 0.001) and a higher median disability score (22.0 versus 14.0, respectively; P < 0.001) 
at 6 months.
Conclusion Untreated depression in people with tuberculosis was associated with worse treatment outcomes, poorer quality of life and 
greater disability. Health workers should be given the support needed to provide depression care for people with tuberculosis.
a School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, PO Box 1985, Bahir Dar, Ethiopia.
b Centre for Global Mental Health, King’s College London, London, England.
c Department of Psychiatry, Addis Ababa University, Addis Ababa, Ethiopia.
Correspondence to Fentie Ambaw (email: fentambaw@yahoo.com).
(Submitted: 15 February 2017 – Revised version received: 18 December 2017 – Accepted: 19 December 2017 – Published online: 5 February 2018 )
Bull World Health Organ 2018;96:243–255| doi: http://dx.doi.org/10.2471/BLT.17.192658244
Research
Depression and tuberculosis treatment in Ethiopia Fentie Ambaw et al.
and 12 were health centres. Facilities 
were eligible for inclusion if they had 
staff trained in mhGAP, including the 
detection and treatment of depression. 
We recruited study participants within 
1 month of starting antituberculosis 
treatment and who: (i) were aged 
18 years or older; (ii) had no plans to 
move out of the study area; (iii) were 
well enough to be interviewed, as judged 
by the interviewer or prospective par-
ticipant; (iv) had not been an inpatient 
for more than 5 days in the previous 
month; and (vi) had not been diagnosed 
with multidrug-resistant tuberculosis. 
Between 23 December 2014 and 4 Feb-
ruary 2015, we consecutively invited 
people who fulfilled these criteria to 
participate in the study by health profes-
sionals running tuberculosis clinics at 
the study centres. Trained nurse research 
assistants provided those willing to par-
ticipate with detailed information and 
obtained written informed consent or 
witnessed a thumb print at data collec-
tion. In Ethiopia, all people with newly 
diagnosed tuberculosis are treated using 
the directly observed treatment, short 
course (DOTS) approach: a combina-
tion of rifampicin, ethambutol, isoniazid 
and pyrazinamide is administered for 
the first 2 months and, subsequently, a 
combination of rifampicin and isoniazid 
is given for an additional 4 months.18
Study variables
The primary outcome variable was treat-
ment default: a patient who defaulted 
was defined by the Ethiopian Federal 
Ministry of Health as one “who has been 
on treatment for at least four weeks and 
whose treatment was interrupted for 
eight or more consecutive weeks”.18 The 
timing of treatment default was taken 
to be midway between the last success-
ful attempt to contact the person and 
the first unsuccessful attempt. Other 
treatment variables were treatment 
success, treatment failure and death 
due to any cause. Treatment was defined 
as successful if either the patient was 
cured (i.e. the sputum smear or culture 
became negative during, or in the last 
month of, treatment) or the treatment 
course was completed. Treatment was 
defined as having failed if the sputum 
smear or culture was positive 5 months 
or later after the start of treatment or a 
multidrug-resistant strain was present, 
irrespective of sputum smear or culture 
findings. Data on these variables were 
obtained from each centre’s tuberculosis 
register, which did not contain informa-
tion after the time of referral on patients 
who were transferred to another area. 
The study protocol has been published 
elsewhere.19
The secondary outcome variables 
were quality of life and disability, 
which were assessed on three occasions 
over 6 months: (i) at baseline, at the 
start of the intensive treatment phase; 
(ii) at 2 months, after completion of 
the intensive treatment phase; and 
(iii) at 6 months, after completion of all 
tuberculosis treatment. Quality of life 
was assessed from responses to the ques-
tion, “How would you rate your health-
related quality of life?” and scored from 
zero for worst imaginable to 10 for best 
Table 1. Sociodemographic characteristics of participants, study of the association 
between depression and tuberculosis treatment outcomes, Ethiopia, 2014–
2016
Sociodemographic characteristic No. of participants (%)a n = 648
Sex
  Male 348 (53.7)
  Female 300 (46.3)
Age in years, mean (SD) 30 (16.0)
Marital status
  Single 210 (32.4)
  Married 358 (55.3)
  Widowed or divorced 80 (12.4)
Educational level
  No formal education 224 (34.6)
  Primary education 260 (40.1)
  Secondary education or higher 164 (25.3)
Occupation
  Unemployed 37 (5.7)
  Government employee 61 (9.4)
  Self-employed 133 (20.5)
  Farmer 172 (26.5)
  Student 39 (6.0)
  Homemaker 111 (17.1)
  Day labourer 44 (6.8)
  Other 51 (7.9)
Annual household income in Ethiopian birr, 
mean (SD)b
9 444 (13 200)
Religion
  Christian 429 (66.2)
  Muslim 219 (33.8)
Residence
  Urban 364 (56.2)
  Rural 284 (43.8)
Ethnicity
  Amhara 306 (47.2)
  Gurage 192 (29.6)
  Mareko 68 (10.5)
  Silte 65 (10.0)
  Other 17 (2.6)
Perceived social support
  Oslo-3 scale score, mean (SD)c 10 (4)
  Tuberculosis stigma scale score, mean (SD)d 26 (10)
SD: standard deviation.
a  All values in the table represent absolute numbers and percentages unless otherwise stated.
b  In 2016, 1 Ethiopian birr = 22.5 United States dollars.
c  The Oslo-3 scale score indicates the participant’s perceived level of social support (range: 3 to 14), with a 
high score indicating better perceived social support.32
d  Tuberculosis stigma was assessed at 2 months in 592 participants using a 10-item scale (range: 10 to 50), 
on which a high score indicated a high level of stigma.
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imaginable.20 Such single-item methods 
have been used successfully in popula-
tion surveys, clinical settings and clini-
cal interviews and found to be valid in 
indicating vulnerability to death due to 
all causes.21,22 No validated, tuberculosis-
specific, quality-of-life instrument is 
available. Disability was assessed using 
the interviewer-administered version of 
the 12-item WHO Disability Assessment 
Schedule, version 2.0.23 This tool has 
been shown to be useful for assessing 
disability in primary care patients with 
depression and is able to capture changes 
over time.24,25 Moreover, it has been 
validated in Ethiopia and showed con-
vergent validity with other predictors 
of impaired functioning in people with 
depression.26 At the three assessments, 
health professionals asked respondents 
if they were being treated for any mental 
illness, including depression.
Our exposure variable was prob-
able depression which was identified 
using the nine-item version of the 
Patient Health Questionnaire and de-
fined conservatively as a score of 10 or 
above.27,28 The nine-item version has 
been validated in two different treatment 
settings in Ethiopia.28,29 In the baseline 
assessment in our study, this version 
of the questionnaire was found to have 
construct validity and acceptable inter-
nal consistency, with an α of 0.81 and a 
mean inter-item correlation coefficient 
of 0.33.6 Participants who responded 
positively to the questionnaire item on 
suicidal ideation were referred for evalu-
ation and treatment to health workers 
who had received training in mental 
health care as part of WHO’s mhGAP.30
We took into account a range of 
possible confounding variables such 
as age, sex, educational level, house-
hold income, marital status, religion, 
ethnicity and place of residence (i.e. 
urban versus rural). Data on these vari-
ables were obtained at baseline using a 
structured questionnaire. The duration 
of tuberculosis symptoms before diag-
nosis was self-reported by participants 
at baseline and information on the type 
of tuberculosis infection (i.e. pulmonary 
or extrapulmonary) was obtained from 
tuberculosis registers. The presence of 
any diagnosed comorbid chronic ill-
nesses was also reported by participants 
themselves and whether or not they 
had an HIV infection, was recorded in 
tuberculosis registers. Use of substances, 
such as alcohol, tobacco and khat, was 
assessed using WHO’s Alcohol, Smoking 
and Substance Involvement Screening 
Test, version 3.1.31
Each participant’s perceived level of 
social support was assessed at baseline 
using the three-item Oslo-3 scale, which 
ranges from 3 to 14, with a high score 
indicating better perceived social sup-
port.32 This scale has previously been 
reported to work well in tuberculosis 
patients in Ethiopia.33 In addition, we 
assessed the stigma of tuberculosis at 
2 months by adapting a 10-item tuber-
culosis stigma scale34 translated into 
Amharic;19 a high score indicated a high 
level of stigma. We also assessed partici-
pants’ perceptions about tuberculosis at 
2 months: perceived tuberculosis sever-
ity was categorized as mild, moderate 
or severe; tuberculosis treatment was 
perceived as not helpful; somewhat 
helpful; or very helpful; and perceived 
barriers to tuberculosis treatment were 
identified from a yes or no answer to the 
question: “Are there barriers to taking 
your medications as prescribed?”
Data analysis
Study variables and the participants’ 
characteristics are presented using 
descriptive statistics. We estimated the 
association between probable depres-
sion at baseline and treatment default, 
treatment success and death using mul-
tivariate Poisson regression analysis with 
a robust variance estimator and present 
the results as risk ratios.35 The follow-up 
time was included as a weighting vari-
able in the analysis of these outcomes. 
We did not perform multivariate analy-
sis for treatment failure because there 
were only six cases. We assessed differ-
ences in quality-of-life and disability 
scores between participants with and 
without probable depression at baseline 
and at 6 months using the independent 
samples t test and the Mann–Whitney U 
test. To examine the change in health-re-
lated quality-of-life and disability scores 
between tuberculosis diagnosis and the 
end of antituberculosis treatment, we 
used a multilevel, mixed-effects, gener-
alized linear model to fit data from the 
three measurement times (i.e. baseline, 
2 months and 6 months), with the three 
measurement times nested within indi-
viduals and individuals nested within 
each of the 14 primary care centres. 
The analysis was performed using Stata 
Fig. 1. Flowchart, study of the effect of depression on tuberculosis treatment outcomes, 
Ethiopia, 2014–2016
965 people registered for tuberculosis care at 
the 14 primary care facilities during the study 
period (n = 965)
657 people recruited at baseline
594 people assessed at 2 months
532 people assessed at 6 months
304 excluded:
• 45 younger than 18 years
• 21 planning to move out of study area
• 31 had been taking antituberculosis drugs for more than 
1 month
• 30 were inpatients for more than 5 days in the last 
month
• 11 had multidrug-resistant tuberculosis
• 57 were already being retreated
• 9 did not speak a study language
63 left study before 2 months
• 6 treatment default
• 22 died
• 3 refused to participate
• 25 transferred out of study area 
• 7 diagnosis changed
62 left study before 6 months
• 8 treatment default
• 7 died
• 8 refused to participate
• 37 transferred out of study area
• 2 diagnosis changed
4 refused to participate
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version 13.1 (StataCorp LP., College 
Station, United States of America) 
and study findings are reported in ac-
cordance with the Strengthening the 
Reporting of Observational Studies in 
Epidemiology (STROBE) statement.36
We calculated the study sample size 
using Stata version 12.0 for a power of 
80%, a confidence level of 95% and an es-
timated prevalence of treatment default 
among tuberculosis patients without 
depression of 2.5%.37 In addition, the 
sample size had to be sufficient to detect 
a 5.0 percentage point increase in the 
prevalence of treatment default among 
people with comorbid depression when 
the ratio of nonexposure to exposure to 
depression was 2:1. With these param-
eters, the required sample size was 639, 
which was increased to 703 to include 
a 10% contingency for potential losses 
to follow up. The study was approved 
by the Institutional Review Board of 
the College of Health Sciences of Addis 
Ababa University (number 027/14/Psy).
Results
In total, 657 people were recruited. 
However, as 9 people were subsequently 
found to have been misdiagnosed with 
tuberculosis, the study analysis included 
data on only 648. Participants’ ages 
ranged from 18 to 85 years and 53.7% 
(348/648) were male (Table 1). The me-
dian time between starting tuberculosis 
treatment and the first assessment was 
0 days (interquartile range, IQR: 2). 
Face-to-face follow up assessments 
were conducted with 91.4% of those 
with tuberculosis (592/648) at 2 months 
and 82.1% (532/648) at 6 months. The 
median time from the start of antitu-
berculosis treatment to the second as-
sessment was 56 days (IQR: 1) and the 
median time to the third assessment was 
160 days (IQR: 3). Data on treatment 
outcomes at 6 months were available for 
88.7% (575/648) of participants. Overall, 
9.6% (62/648) were transferred out of 
study sites (Fig. 1). At baseline, 53.9% 
(349/648) scored 10 or higher on the 
nine-item Patient Health Questionnaire 
and were classified as having probable 
depression (Table 2) here was no signifi-
cant difference at baseline between those 
who completed the study and those who 
were transferred out in the frequency of 
Table 2. Illness and substance use, study of the effect of depression on tuberculosis 
treatment outcomes, Ethiopia, 2014–2016
Variable No. of participants (%) n = 648
Probable depressiona at baseline 349 (53.9)
Suicidal ideation
  No 535 (82.6)
  Yes 113 (17.4)
Duration of tuberculosis symptoms before 
diagnosis, weeks
   < 2 40 (6.2)
  2–12 338 (52.2)
  13–52 209 (32.3)
   > 52 61 (9.4)
Type of tuberculosis
  Pulmonary 371 (57.3)
  Extrapulmonary 277 (42.8)
HIV status
  Negative 495 (76.4)
  Positive 74 (11.4)
  Unknown 79 (12.2)
Hypertension 1 (0.2)
Heart disease 3 (0.5)
Diabetes mellitus 5 (0.8)
Previous depression 0 (0.0)
Alcohol useb
  Low 562 (86.7)
  Moderate 74 (11.4)
  High 12 (1.9)
Tobacco useb
  Low 615 (94.9)
  Moderate 29 (4.5)
  High 4 (0.6)
Khat useb
  Low 544 (84.0)
  Moderate 93 (14.3)
  High 11 (1.7)
Perceived tuberculosis severityc
  Mild 62 (10.5)
  Moderate 85 (14.4)
  Severe 445 (75.2)
Perceived benefit of tuberculosis treatmentc
  Not helpful 2 (0.3)
  Somewhat helpful 23 (3.9)
  Very helpful 567 (95.8)
Perceived barriers to tuberculosis treatmentc
  No 458 (77.4)
  Yes 134 (22.6)
HIV: human immunodeficiency virus.
a  Probable depression was defined as a score ≥ 10 on the nine-item version of the Patient Health 
Questionnaire.27
b  The use of substances, such as alcohol, tobacco and khat, was assessed at baseline using the World Health 
Organization’s Alcohol, Smoking and Substance Involvement Screening Test, version 3.1.31
c  Participants’ perceptions of tuberculosis severity, the benefit of tuberculosis treatment and barriers to 
tuberculosis treatment were assessed at 2 months in 592 participants.
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probable depression, level of disability 
or quality of life.
At 6 months, the treatment default 
rate was significantly higher among 
participants with probable depression 
at baseline than among those without: 
3.9% (12/309) versus 0.8% (2/266), 
respectively (P < 0.05). Similarly, the 
proportion who had died was signifi-
cantly higher among those with probable 
depression: 7.8% (24/309) versus 1.9% 
(5/266) in those without (P < 0.01). In 
addition, the treatment success rate 
was significantly lower in those with 
probable depression: 87.1% (269/309) 
versus 96.6% (257/266) in those without 
(P  < 0.001; Table 3). On multivariate 
analysis, treatment default by 6 months 
was independently associated with prob-
able depression (adjusted risk ratio, aRR: 
9.09; 95% confidence interval, CI: 6.72 
to 12.30), as was death (aRR: 2.99; 95% 
CI: 1.54 to 5.78). However, there was no 
significant association with treatment 
success (aRR: 0.95; 95% CI: 0.91 to 1.00), 
though the upper confidence bound was 
borderline for significance (Table 4).
Probable depression at baseline 
was also associated with quality of 
life (Fig. 2) and disability (Fig. 3). The 
mean quality-of-life score at baseline 
was lower among those with probable 
depression than among those without 
(4.7 versus 5.7, respectively; P < 0.001) 
and the median disability score was 
higher (30.0 versus 18.0, respectively; 
P < 0.001). These differences remained 
significant at 6 months, when the mean 
quality-of-life score among those with 
and without probable depression was 
5.0 and 6.0, respectively, (P < 0.001) 
and the median disability score was 
22.0 and 14.0, respectively, (P < 0.001; 
Table 3). On multivariate analysis, qual-
ity of life at 6 months was significantly 
and negatively associated with probable 
depression (β = −0.07; 95% CI: −0.07 
to −0.06) and disability was positively 
associated (β = 0.83; 95% CI: 0.67 to 
0.99). There was no significant change 
over time in either mean quality-of-life 
score (β = −0.02; 95% CI: −0.13 to 0.09) 
or median disability score (β = −0.07; 
95% CI: −0.33 to 0.22; Table 5). Data on 
factors other than depression that were 
associated with tuberculosis treatment 
outcomes are shown in Table 4 and data 
on factors associated with quality of life 
and disability are shown in Table 5.
Discussion
Our study provides evidence that people 
with tuberculosis in Ethiopia who had 
probable depression at the start of treat-
ment were significantly more likely to 
default on treatment or die. Moreover, 
their chance of successful treatment 
was lower. Previous studies have also 
reported that depression compromises 
adherence to essential scheduled health 
care.11 With tuberculosis, treatment 
default leads to transmission of the 
infection to others, thereby raising the 
odds of further defaults,38 and increases 
the risk of multidrug-resistant disease.39
In agreement with our observations, 
systematic reviews and large population-
based studies in both high- and low-in-
come settings have found that mortality 
is increased in people with depression 
and that the association is maintained 
across patient groups.40–43 However, 
depression is a more serious concern 
for people with tuberculosis in Ethiopia 
because comorbid depression has been 
found in the majority.6 The mechanism 
by which depression increases mortality 
is likely to be complex. Although 113 
of our 648 study participants reported 
suicidal ideation, we were not able to 
confirm its contribution to the mortal-
ity observed. One systematic review 
found that suicide contributed to less 
than 1.0% of deaths in medical samples 
like ours.41 Moreover, in our study 
Table 3. Tuberculosis treatment outcomes, by presence of probable depression, Ethiopia, 2014–2016
Indicator Participantsa P
With probable depression at 
baseline(n = 309)
Without probable depression at 
baseline(n = 266)
Treatment outcome, no. (%)
  Treatment success 269 (87.1) 257 (96.6) < 0.001
  Treatment failure 4 (1.3) 2 (0.8) ND
  Treatment default 12 (3.9) 2 (0.8) < 0.05
  Death 24 (7.8) 5 (1.9) < 0.01
Quality-of-life score, mean  (SD)b,c
  At baseline before tuberculosis treatment 4.7 (2.7) 5.7 (2.4) < 0.001
  After 6 months of treatment 5.0 (2.4) 6.0 (2.2) < 0.001
Disability score, median(IQR)c,d
  At baseline before tuberculosis treatment 30 (16) 18 (8) < 0.001
  After 6 months of treatment 22 (19) 14 (4) < 0.001
IQR: interquartile range; ND: not determined; SD: standard deviation.
a  Treatment outcomes were known at 6 months for 575 of the 648 study participants: those who refused to be tested, were transferred to another area or whose 
diagnosis changed were excluded.
b  Quality of life was assessed using the question, “How would you rate your health-related quality of life?” and scored from 0 (worst) to 10 (best).
c  Quality-of-life and disability were assessed in 648 participants at baseline and in 532 at 6 months.
d  Disability was assessed using the interviewer-administered version of the 12-item World Health Organization Disability Assessment Schedule, version 2.0 (score 
range: 0 to 60).23
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area, the commonest cause of death 
in people with severe mental illness 
is infectious disease.44 In people with 
tuberculosis, depression may increase 
mortality through decreased self-care, 
including failure to take medications 
as prescribed,11 and through disability 
leading to poverty and substandard liv-
ing conditions. One possible biological 
mechanism is depression-associated 
immune suppression.45
We also found that probable depres-
sion in people with tuberculosis was 
associated with poorer quality of life 
and greater disability, both at the start 
and after completion of antituberculosis 
treatment. In previous studies, neither 
quality of life nor the degree of dis-
ability returned to levels normal for the 
population by the end of tuberculosis 
treatment.8,46 Possible explanations are 
underlying depression, the quality of 
tuberculosis care falling short of interna-
tional standards and the socioeconomic 
consequences of the illness and its as-
sociated stigma.47,48 One implication of 
these findings is that evaluating disabil-
ity only during episodes of tuberculosis 
is likely to underestimate the disease 
burden as continuing disability after 
clinically successful treatment would 
be ignored.49
The treatment default rate we ob-
served was markedly lower in females, 
rural residents and people living with 
HIV. Treatment adherence may have 
been stronger in people with an HIV 
infection, because of the counselling and 
additional support given to them in the 
Ethiopian health-care system, particu-
larly in rural communities.50 Treatment 
default was also associated with higher 
khat use, substance use has previously 
been found to reduce the tuberculosis 
treatment success rate.51 In Ethiopia, the 
implementation of integrated care for 
people with mental, neurological and 
substance use disorders does not include 
khat use disorder as a target condition, 
because little is known about its adverse 
consequences and, because practical 
interventions are lacking. The level of 
disability was higher in females, in par-
ticipants who perceived their episode 
of tuberculosis as severe, in those with 
pulmonary rather extrapulmonary tu-
berculosis and in those with a high level 
of stigma, indicating that both physical 
and psychosocial factors may contribute 
to the development of disability.52
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Although we found that comorbid 
depressive symptoms in people with 
tuberculosis are often associated with 
poorer outcomes, even with successful 
treatment, generally health-care provid-
ers in Ethiopia do not assess depression 
in these people or provide evidence-
based treatment. Consequently, unno-
ticed comorbid depressive symptoms 
may hamper efforts to end tuberculosis. 
National tuberculosis treatment guide-
lines may need to address depressive 
symptoms directly and health profes-
sionals should be trained to detect and 
treat depression in the context of the 
disease.
Our study has several of limitations. 
In our sample size calculation, we as-
sumed that the tuberculosis treatment 
default rate in people without depression 
was 2.5%, which was based on a national 
report. We found a rate of 0.8%. Howev-
er, we were still able to obtain estimates 
even with this sample size and do not 
believe it critically affected our findings. 
Second, in the low-income setting of our 
study, participants could have had un-
diagnosed, comorbid physical illnesses. 
Third, as we did not know whether or 
not participants were treated for depres-
sion outside the study centres, we may 
have overestimated the frequency of un-
treated depression. Nonetheless, as few 
people with depression receive treatment 
in Ethiopia, it is unlikely that misclassifi-
cation of untreated depression seriously 
affected our results. Fourth, poverty 
may not have been fully captured by our 
sociodemographic variables and may 
have been a confounding factor. Fifth, as 
quality of life was assessed using a single 
question, no detailed information on dif-
ferent dimensions of quality of life was 
available. Sixth, we had no information 
on whether participants transferred out 
of the study area differed significantly 
from others in treatment outcomes or 
final quality-of-life or disability scores. 
However, there were no differences at 
baseline. Finally, our conclusions cannot 
be extended to tuberculosis patients who 
are hospitalized, are being retreated, or 
have multidrug-resistant disease. 
Nevertheless, consecutive patients 
were recruited and our study sample 
was reasonably representative, because 
several sites were included, all eligible 
people were invited to participate and 
data were collected over a long enough 
period to take seasonal variations into 
account.53 Use of the DOTS approach 
Fig. 2. Change in quality of life with tuberculosis treatment, by depression at baseline, 
Ethiopia, 2014–2016
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Note: Quality of life was assessed on the basis of responses to the question, “How would you rate your 
health-related quality of life?” and scored from 0 (worst) to 10 (best).
Fig. 3. Change in disability score with tuberculosis treatment, by depression at 
baseline, Ethiopia, 2014–2016
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Note: Disability was assessed using the interviewer-administered version of the 12-item World Health 
Organization Disability Assessment Schedule, version 2.0 (score range: 0–60).23
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Table 5. Factors associated with health-related quality of life and disability, study of the effect of depression on tuberculosis treatment 
outcomes, Ethiopia, 2014–2016
Factor Quality-of-life scorea Disability scoreb
Crude β (95% CI)c Adjusted β (95% CI)c Crude β (95% CI)c Adjusted β (95% CI)c
PHQ-9 score,d per 
1-point increase
−0.08 (−0.11 to −0.05) −0.07 (−0.07 to −0.06) 0.92 (0.69 to 1.15) 0.83 (0.67 to 0.99)
Time after start 
of tuberculosis 
treatment
0.05 (−0.06 to 0.16) −0.02 (−0.13 to 0.09) −0.95 (−1.29 to −0.61) −0.07 (−0.33 to 0.22)
Sex
  Male Reference Reference Reference Reference
  Female −0.14 (−0.44 to 0.15) −0.04 (−0.18 to 0.11) 1.67 (0.48 to 2.86) 0.51 (0.09 to 0.93)
Age
  Below median Reference Reference Reference Reference
  Median and above −0.39 (−0.94 to 0.16) −0.10 (−0.47 to 0.28) 3.37 (−0.42 to 7.16) 1.26 (−0.78 to 3.29)
Tuberculosis symptoms duration before diagnosis, weeks
  < 2 1.02 (0.31 to 1.72) 0.42 (−0.27 to 1.11) −6.89 (−11.13 to −2.65) −2.37 (−4.08 to −0.66)
  2–12 0.22 (0.05 to 0.27) −0.18 (−0.76 to 0.40) −2.88 (−4.41 to −1.36) −0.77 (−1.98 to 0.45)
  13–52 0.01 (−0.24 to 0.27) −0.42 (−0.98 to 0.15) −1.79 (−2.82 to −0.75) −0.43 (−0.78 to −0.07)
  > 52 Reference Reference Reference Reference
Household income
  Below median Reference Reference Reference Reference
  Median and above 0.98 (0.75 to 1.21) 0.46 (0.45 to 0.47) −1.39 (−2.67 to −0.11) 0.07 (−0.04 to 0.18)
Residence
  Urban Reference Reference Reference Reference
  Rural −0.47 (−1.00 to 0.07) −0.35 (−0.47 to −0.22) 1.63 (1.10 to 2.15) −0.01 (−1.20 to 1.19)
Type of tuberculosis
  Pulmonary Reference Reference Reference Reference
  Extrapulmonary 0.14 (−0.25 to 0.53) −0.05 (−0.13 to 0.03) −1.76 (−2.41 to −1.11) −0.92 (−1.38 to −0.46)
Educational level
  No formal education −1.00 (−1.23 to −0.77) −0.22 (−0.62 to 0.18) 5.66 (2.43 to 8.89) 1.47 (0.55 to 2.39)
  Primary education −0.51 (−0.55 to −0.47) −0.12 (−0.24 to 0.00) 1.45 (−0.28 to 3.18) −0.47 (−1.14 to 0.20)
Secondary education 
or higher
Reference Reference Reference Reference
Perceived tuberculosis severity
  Mild Reference Reference Reference Reference
  Moderate −0.27 (−0.52 to −0.03) −0.38 (−0.43 to −0.32) −0.26 (−1.37 to 0.85) 0.22 (−0.80 to 1.23)
  Severe −0.74 (−1.10 to −0.37) −0.45 (−0.58 to −0.33) 4.39 (3.23 to 5.56) 2.54 (1.37 to 3.71)
Perceived barriers to tuberculosis treatment
  No Reference Reference Reference Reference
  Yes −0.41 (−1.17 to 0.35) −0.12 (−0.68 to 0.45) 3.24 (2.18 to 4.31) 1.44 (−0.05 to 2.93)
Religion
  Christian Reference Reference Reference Reference
  Muslim 0.09 (−0.06 to 0.24) 0.11 (−0.12 to 0.34) 1.48 (0.09 to 2.87) 1.78 (1.66 to 1.90)
Marital status
  Single Reference Reference Reference Reference
  Married 0.06 (−0.94 to 1.07) 0.40 (0.03 to 0.77) 2.20 (−3.02 to 7.41) −0.51 (−1.67 to 0.64)
  Widowed or divorced −0.99 (−1.9 to −0.77) −0.33 (−0.81 to −0.14) 5.42 (−1.56 to 12.39) 0.75 (−2.14 to 3.64)
HIV status
  Negative Reference Reference Reference Reference
  Positive −0.36 (−0.64 to −0.08) −0.06 (−0.11 to −0.00) 1.82 (−0.54 to 4.17) 0.63 (−0.99 to 2.25)
  Unknown 0.26 (0.23 to 0.28) 0.23 (0.09 to 0.38) −0.63 (−1.40 to 0.30) −0.13 (−0.29 to 0.04)
Alcohol usee
  Low Reference Reference Reference Reference
  Moderate or high −0.09 (−0.46 to 0.29) 0.13 (−0.55 to 0.82) 0.68 (−0.28 to 1.64) 0.96 (−0.06 to 1.97)
(continues. . .)
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to tuberculosis treatment in Ethiopia 
means that our findings are generaliz-
able to settings in low- and middle-
income countries using a similar ap-
proach.
In conclusion, untreated depression 
appears to be a strong risk factor for 
treatment default and death in people 
with newly diagnosed tuberculosis and 
is associated with poor health-related 
quality of life and greater disability, de-
spite successful tuberculosis treatment. 
Consequently, health-care workers 
should be given the support needed to 
provide depression care for people with 
tuberculosis. ■
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Factor Quality-of-life scorea Disability scoreb
Crude β (95% CI)c Adjusted β (95% CI)c Crude β (95% CI)c Adjusted β (95% CI)c
Khat usee
  Low Reference Reference Reference Reference
  Moderate or high −0.13 (−0.36 to 0.11) −0.24 (−0.44 to −0.04) −0.80 (−0.89 to −0.71) −0.98 (−1.31 to −0.65)
Perceived social support
Oslo-3 scale score, 
per 1-point increasef
0.27 (0.20 to 0.34) 0.20 (0.14 to 0.25) −0.39 (−0.82 to 0.04) 0.05 (−0.36 to 0.47)
Tuberculosis stigma 
scale score, per 
1-point increaseg
−0.09 (−0.15 to −0.03) −0.03(−0.08 to −0.01) 0.45 (0.39 to 0.51) 0.16 (0.15 to 0.16)
CI: confidence interval; HIV: human immunodeficiency virus; PHQ-9: nine-item version of the Patient Health Questionnaire.
a  Quality of life was assessed on the basis of responses to the question, “How would you rate your health-related quality of life?” and scored from 0 (worst) to 10 (best).
b  Disability was assessed using the interviewer-administered version of the 12-item World Health Organization Disability Assessment Schedule, version 2.0 (score 
range: 0 to 60).23
c  The β values were derived using a multilevel, mixed-effects, generalized linear model.
d  Probable depression at baseline was defined as a score ≥ 10 on PHQ-9, on which scores ranged from 0 to 27.27
e  The use of substances, such as alcohol and khat, was assessed using the World Health Organization’s Alcohol, Smoking and Substance Involvement Screening Test, 
version 3.1.31
f  A high score on the Oslo-3 scale indicates better perceived social support.32
g  A high score indicates greater stigma.
صخلم
ايبويثإ في ةقاعلإاو ةايلحا ةيعونو ،لسلا جلاع جئاتنو جلاعلما يرغ بائتكلاا
 جلاع  جئاتنو  ضيرلما  بائتكلاا  ينب  ةقلاعلا  ءاصقتسا  ضرغلا
.ايبويثإ في زجعلاو ةايلحا ةدوجو ،لسلا
 ينعضالخا  نم  لياوتلا  لىع  اًغلاب 648  ةساردلا  نمضتت  ةقيرطلا
 مييقت مت .ةيحصلا ةياعرلا يرفوتل اًيسيئر اًقفرم 14 في لسلا جلاعل
 نيرهش  رورم  دعبو  )ساسلأا  طخ  يأ(  جلاعلا  ءدب  في  عيملجا
 10  نم  سايقم  لىع  لمتحلما  بائتكلاا  انددح  دقو  .رهشأ 6و
 متو  .صرانع 9  نم  نوكلما  ضيرلما  ةحص  نايبتسا  لىع  لىعأ  وأ
 فلختلا وأ هلشف وأ جلاعلا حاجنب ةقلعتلما تانايبلا لىع لوصلحا
 سايقم مادختساب ةايلحا ةيعون مييقت متو .لسلا تلاجس نم هنع
 لودج  مادختساب  زجعلا  جئاتن  باسحب  انمقو  يصربلا  يرظنلا
 ليلتح  مادختسابو  .ةيلماعلا  ةحصلا  ةمظنمب  صالخا  زجعلا  مييقت
 بائتكلاا ينب ةقلاعلا مييقتب انمق ،تايرغتلما ددعتم نوساوب رادحنا
.ةافولا تلااحو جلاعلا جئاتنو ساسلأا طخ في لمتحلما
 لقتسم لكشب ساسلأا طخ في جلاعلما يرغ بائتكلاا طبترا جئاتنلا
 ؛aRR: 9.09 ،ةححصلما ةروطلخا ةبسن( لسلا جلاع نع فلختلاب
 ةافولا تلااح ،)12.30 لىإ 6.72 :% 95 اهرادقم ةيحجرأ ةبسنب
 ،)5.78 لىإ 1.54 :% 95 اهرادقم ةيحجرأ ةبسنب ؛aRR: 2.99(
 0.67 :95%  اهرادقم ةيحجرأ ةبسنب  ؛0.83  :اتيب( بركلأا زجعلا
 ةيحجرأ  ةبسنب  ؛-0.07  :اتيب(  أوسلأا  ةايلحا  ةيعونو  )0.99  لىإ
 نوكراشلما نياعي .رهشأ 6 في )-0.06 لىإ -0.07 :% 95 اهرادقم
 لقأ ةايح ةيعون ةجيتن طسوتم نم لمتحلما بائتكلاا باحصأ نم
 6.0  لباقم  في  5.0(  بائتكلاا  نم  نوناعي  لا  نيذلا  ءلاؤه  نم
 لىعأ ةيطسو زجع ةجيتنو )0.001<  لماتحلاا ةبسن ؛لياوتلا  لىع
 في )0.001< لماتحلاا ةبسن ؛لياوتلا لىع 14.0 لباقم في 22.0(
.رهشأ 6
 جلاع جئاتنب لسلا ضىرم ىدل جلاعلما يرغ بائتكلاا طبتري جئاتنلا
 لامج في ينلماعلا حنم بيجو .بركأ زجعو ،أوسأ ةايح ةيعونو ،أوسأ
.لسلا ضىرلم بائتكلاا جلاع يرفوتل مزلالا معدلا ةحصلا
(. . .continued)
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摘要
埃塞俄比亚未治疗抑郁症与肺结核治疗结果、生活质量和残疾程度的关系
目的 调查埃塞俄比亚共病抑郁与肺结核治疗结果、生
活质量和残疾程度之间的关系。
方法 这项研究涉及 648 位连续在 14 个初级医疗机构
接受肺结核治疗的成人。在治疗开始（即基准）和之
后的 2 个月和 6 个月对所有患者进行了评估。我们在
九项患者健康问卷中将潜在抑郁定义为 10 分或以上。
从结核病登记处获得治疗常规、失败、成功和死亡数
据。我们使用视觉模拟量表评估了生活质量，并使用
世界卫生组织的残疾评估量表计算了残疾评分。我们
使用多元 Poisson 回归分析，估计了基准处潜在抑郁、
治疗结果和死亡之间的关联。
结果 在 6 个月时，未治疗抑郁症的基准评估与肺结
核治疗常规之间具有独立相关性（调整后的风险比，
aRR: 9.09；95% 置信区间，CI: 6.72 至 12.30），死亡（aRR: 
2.99；95% CI: 1.54 至 5.78），更高的残疾程度（β: 0.83；
95% CI: 0.67 至 0.99）和更差的生活质量（β: ‑0.07 ；
95% CI: ‑0.07 至 ‑0.06）。在 6 个月时，有潜在抑郁症的
参与者的平均生活质量评分低于没有潜在抑郁症的参
与者（分别为 5.0 和 6.0 ；P < 0.001），且其中位残疾评
分更高（分别为 22.0 和 14.0 ；P < 0.001）。
结论 结核病患者的未治疗抑郁症与较差的治疗效果、
较低的生活质量和较高的残疾程度有关。应给予医疗
工作者必要的支持，为结核病患者提供抑郁症护理。
Résumé
Dépression non traitée et résultats du traitement contre la tuberculose, qualité de vie et handicap, Éthiopie
Objectif Étudier l’association entre la dépression et les résultats du 
traitement contre la tuberculose, la qualité de vie et le handicap en 
Éthiopie.
Méthodes L’étude a porté sur 648 adultes consécutifs traités contre la 
tuberculose dans 14 établissements de soins primaires. Tous ont été 
examinés au début du traitement (période de référence) puis au bout de 
2 et 6 mois. Nous avons défini la dépression probable comme l’obtention 
d’un score de 10 ou plus au Questionnaire sur la santé du patient PHQ-9. 
Les registres sur la tuberculose ont fourni des données sur les défauts, 
l’échec ou la réussite des traitements ainsi que sur les décès. La qualité 
de vie a été évaluée au moyen d’une échelle visuelle analogique et nous 
avons calculé le score de handicap à l’aide de l’échelle d’évaluation du 
handicap (Disability Assessment Scale) de l’Organisation mondiale de la 
Santé. À l’aide d’une analyse de régression de Poisson multivariée, nous 
avons estimé l’association entre une dépression probable au début du 
traitement, les résultats du traitement et le décès.
Résultats Une dépression non traitée au début du traitement était 
associée de façon indépendante avec des défauts de traitement contre 
la tuberculose (risque relatif ajusté, RRa: 9,09; intervalle de confiance 
(IC) de 95%: 6,72 à 12,30), le décès (RRa: 2,99; IC 95%: 1,54 à 5,78), 
une augmentation du handicap (β: 0,83; IC 95%: 0,67 à 0,99) et une 
moins bonne qualité de vie (β: −0,07; IC 95%: −0,07 à −0,06) au bout 
de 6 mois. Les participants souffrant probablement d’une dépression 
avaient un score moyen de qualité de vie inférieur à ceux n’en souffrant 
pas (respectivement 5,0 contre 6,0; P < 0,001) et un score de handicap 
médian plus élevé (respectivement 22,0 contre 14,0; P < 0,001) au 
bout de 6 mois.
Conclusion La dépression non traitée chez les personnes atteintes 
de tuberculose était associée à de moins bons résultats du traitement, 
à une moins bonne qualité de vie et à un plus grand handicap. Les 
professionnels de santé devraient recevoir l’aide nécessaire pour 
proposer une prise en charge de la dépression aux personnes atteintes 
de tuberculose.
Резюме
Невылеченная депрессия и результаты лечения туберкулеза, качество жизни и инвалидизация, 
Эфиопия
Цель Изучить взаимосвязь между сопутствующей депрессией 
и результатами лечения туберкулеза, качеством жизни и 
инвалидизацией в Эфиопии.
Методы В исследовании участвовали 648 взрослых пациентов с 
туберкулезом, последовательно поступивших в 14 учреждений 
первичной медико-санитарной помощи. Все они прошли 
оценку в начале лечения (т. е. на исходном уровне), затем 
через 2 и 6 месяцев. Авторы считали депрессию вероятной, 
если пациент набирал 10 баллов и выше по шкале опросника 
о здоровье пациента, состоящей из 9 пунктов. Данные о 
прекращении лечения, отсутствии эффективности лечения, 
успешном лечении и летальных исходах были получены из 
журналов регистрации больных туберкулезом. Качество жизни 
оценивалось с использованием визуальной аналоговой шкалы, 
а степень инвалидизации была рассчитана по шкале оценки 
инвалидизации Всемирной организации здравоохранения. 
Используя многовариантный регрессионный анализ Пуассона, 
мы оценили взаимосвязь между вероятной депрессией на 
исходном уровне, результатами лечения и летальным исходом.
Результаты Наличие невылеченной депрессии на исходном 
уровне спустя 6 месяцев было независимо связано с 
прекращением лечения туберкулеза (скорректированный 
относительный риск, сОР: 9,09; 95%-й доверительный интервал, 
ДИ: от 6,72 до 12,30), с летальным исходом (сОР: 2,99; 95%-й ДИ: от 
1,54 до 5,78), с более высокой степенью инвалидизации (β: 0,83; 
95%-й ДИ: от 0,67 до 0,99) и с более низким качеством жизни (β: 
-0,07; 95%-й ДИ: от -0,07 до -0,06). Через 6 месяцев у пациентов 
с вероятной депрессией был более низкий средний показатель 
качества жизни, чем у пациентов без нее (5,0 против 6,0 
соответственно, P < 0,001), и более высокий средний показатель 
степени инвалидизации (22,0 против 14,0 соответственно, 
P < 0,001).
Вывод Невылеченная депрессия у людей с туберкулезом 
была связана с худшими результатами лечения, более низким 
качеством жизни и большей степенью инвалидизации. 
Медицинским работникам должна быть предоставлена 
необходимая поддержка для оказания помощи при депрессии 
людям, больным туберкулезом.
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Resumen
Resultados del tratamiento de la tuberculosis y la depresión sin tratar, calidad de vida y discapacidad, Etiopía
Objetivo Para investigar la asociación entre los resultados de la 
depresión concomitante y el tratamiento de la tuberculosis, la calidad 
de vida y la discapacidad en Etiopía.
Métodos El estudio incluyó 648 adultos consecutivos tratados contra la 
tuberculosis en 14 centros sanitarios primarios. Todos fueron evaluados 
en la iniciación del tratamiento (es decir, el principio) y tras 2 y 6 meses. 
Definimos la posible depresión como una puntuación de 10 o más en 
el Cuestionario de Salud del Paciente de nueve elementos. Los datos 
del defecto, incumplimiento y éxito del tratamiento y de la defunción 
se obtuvieron de los registros de la tuberculosis. La calidad de vida 
se evaluó usando una ampliación análoga visual y calculamos la 
puntuación de discapacidad usando la Ampliación de Asesoramiento 
de Discapacidad de la Organización Mundial de la Salud. Usando el 
análisis de regresión de Poisson multivariable, estimamos la asociación 
entre la posible depresión al principio y los resultados del tratamiento 
y la defunción.
Resultados  La depresión sin tratar al  pr incipio estaba 
independientemente asociada con el defecto del tratamiento de la 
tuberculosis (coeficiente de riesgo ajustado, aRR: 9,09; intervalo de 
confianza, IC, del 95%: 6,72 a 12,30), defunción (aRR: 2,99; IC del 95%: 
1,54 a 5,78), mayor discapacidad (β: 0,83; IC del 95%: 0,67 a 0,99) y 
calidad de vida más pobre (β: −0,07; IC del 95%: −0,07 a −0,06) en 6 
meses. Los participantes con posible depresión tuvieron una puntuación 
de calidad de vida media más baja que aquellos sin (5,0 frente a 6,0, 
respectivamente; P < 0.001) y una puntuación de discapacidad media 
más alta (22,0 frente a 14,0, respectivamente; P < 0.001) en 6 meses.
Conclusión La depresión sin tratar en las personas con tuberculosis se 
asoció con los peores resultados del tratamiento, una calidad de vida 
más pobre y mayor discapacidad. Deberían darles el respaldo necesario 
a los trabajadores sanitarios para ofrecer atención a la depresión para 
personas con tuberculosis.
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